Exciting News! Our Gainesville Office has moved to Bristow – 9450 Innovation Drive, Manassas, VA 20110. Same great providers and care team, same exceptional care, new, larger space to better serve our patients.
A radioconjugate containing the tracer PEG6-IPQA labeled with fluorine F 18 for potential tumor imaging using positron emission tomography (PET). Upon administration, the IPQA moiety of fluorine F 18 fluoro-PEG6-IPQA selectively targets and irreversibly binds to the constitutively active mutant L858R of epidermal growth factor receptor (EGFR) kinase, thereby allowing the visualization of tumor cells expressing the active mutant L858R EGFR using PET. This can be used to select EGFR kinase inhibitors that bind in a similar manner as this tracer and may allow individualized therapy for patients that respond well to these types of EGFR kinase inhibitors. The presence of the L858R EGFR mutation in non-small cell lung cancer (NSCLC) cells is correlated with a better response to EGFR kinase inhibitors compared to wild-type (WT) or L858R/T790M EGFR dual-mutant. Check for active clinical trials using this agent.
Related Posts
Recent Posts
